Oruka Therapeutics
ORKA
15 hedge funds and large institutions have $21.3M invested in Oruka Therapeutics in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
24% less capital invested
Capital invested by funds: $27.9M → $21.3M (-$6.59M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$677K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.76K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$4.88K |
| 4 |
Walleye Trading
New York
|
+$4.07K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$83K |
| 2 |
Citigroup
New York
|
-$814 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $5.07M | – | – | – |
|
2
Franklin Resources
San Mateo,
California
| $4.17M | – | – | – |
|
|
VMI
3
VHCP Management II
New York
| $3.74M | – | – | – |
|
|
TCM
4
Tekla Capital Management
Boston,
Massachusetts
| $2.78M | – | – | – |
|
|
RCM
5
RA Capital Management
Boston,
Massachusetts
| $2.7M | – | – | – |
|
|
VM
6
VHCP Management
New York
| $1.6M | – | – | – |
|
|
RA
7
Royce & Associates
New York
| $617K | +$677K | +832 | New |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| $417K | +$9.76K | +12 | +2% |
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $130K | – | – | – |
|
|
VKH
10
Virtu KCG Holdings
New York
| $54K | +$4.88K | +6 | +9% |
|
|
11
Walleye Trading
New York
| $4K | +$4.07K | +5 | New |
|
|
BFA
12
BlackRock Fund Advisors
San Francisco,
California
| $3K | – | – | – |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $3K | +$2.44K | +3 | +300% |
|
14
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$83K | -82 | Closed |
|
|
16
Citigroup
New York
| – | -$814 | -1 | Closed |
|
ORKA Hedge Fund Activity: Q1 2016 in Review
15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2016, worth a combined $21.3M — down 24% from $27.9M a quarter earlier.
Fund positioning in ORKA was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $677K. The largest seller was Citadel Advisors, exiting entirely with an estimated $83K sold.
- 15 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $21.3M of Oruka Therapeutics stock for Q1 2016, down 24% quarter-over-quarter.
- 2 funds opened new Oruka Therapeutics positions in Q1 2016 and 2 closed out, a net change of 0 holders.
- The largest Oruka Therapeutics buyer in Q1 2016 was Royce & Associates, an estimated $677K added.
- The largest Oruka Therapeutics seller in Q1 2016 was Citadel Advisors, an estimated $83K sold.
Based on aggregated 13F filings for Q1 2016.